JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - GUARDANT HEALTH INC
Financial Performance:
- Revenue drivers include 29% volume growth in Garden 360, >100% YoY growth in Reveal (MRD) tests, and >300% (3x) volume growth in SHIELD.
- Gross margins improved significantly in Q3 due to FDA approval of low-cost, high-throughput SHIELD; COGS dropped from >$400 to $330 per test.
- Target to reduce SHIELD COGS to $200 per test by end of 2028; automation investments expected to drive further labor cost reductions.
- Excluding screening, the non-screening business reached breakeven in 2023 with positive cash flow; screening segment expected to reach breakeven and reduce cash burn in H2 2027.
- Full company Free Cash Flow (FCF) break-even is targeted for Q4 2027.
- Biopharma segment identified as the fastest-growing area, driven by data usage ($1 exabyte expected in a couple of years) and clinical trial monitoring.
Guidance and Future Outlook:
- ADBL (All-Disease Blood Test) for Garden 360 FDA approval expected April 1, 2027, based on a timeline similar to SHIELD's approval cycle.
- SHIELD sales force expansion to reach 600-700 reps (from >400 currently) to support scaling through 2027.
- 2027 anticipated to be the year for a "sizable class" of SHIELD volumes as major payer contracts (United, Cigna, Anthem) come into effect, with United starting in August 2026 and others in Jan 2027.
- Long-term goal involves converging MRD and therapy response monitoring markets as treatments move earlier in the disease continuum.
- Expansion beyond oncology is planned to leverage epigenomic data for detecting 500+ non-oncology diseases (e.g., liver, kidney) in annual checkups.
Business Segments and Product Lines:
- Garden 360: Continued strong performance in late-stage therapy selection; launched 11 new "smart apps" focusing on immune checkpoint inhibitors and PD-L1 blood characterization; pending FDA approval for "Liquid CDX" version expected to catalyze volume in 2027.
- SHIELD: Launched with pharma partners; clinical launch expected by year-end; currently 83,000 tests in Q3 against a market opportunity of 18 million annual tests among 54 million unscreened patients.
- Reveal: Growing via both standalone tissue tests and liquid MRD; new "Reveal Ultra" launched to serve both tumor-informed and tissue-free needs.
- Biopharma & Data: Utilizing large-scale EMR and claims data to develop predictive apps and assist drug companies with early treatment response monitoring and patient segmentation using methylation/epigenomic data.
- Channel Strategy: Prioritizing PCP (Primary Care Physician) channel expansion for non-oncology applications; DTC pilot results exceeded expectations, driving plans to reinvest gross profit into national DTC and influencer strategies.
Market and Competitive Landscape:
- Market opportunity for therapy monitoring in late-stage cancer estimated at millions of tests annually due to the need for serial testing and genetic profiling at every progression.
- Garden 360 tissue test claimed as "best-in-class" by covering genomics, transcriptomics, and methylation with low Q&S rates, driving the largest sequential tissue growth in Q3.
- Payer penetration is critical; currently 100 million covered lives via United, Cigna, and Anthem, with reimbursement wins occurring faster than anticipated.
- USPSCF (US Preventive Services Task Force) guideline inclusion remains a key catalyst for $0 out-of-pocket access and broad utilization, though business can grow without it currently due to existing coverage and state-level legislation.
Risks and Challenges:
- Reimbursement & Policy: Dependence on USPSCF final decision (expected November) for $0 patient cost-sharing; potential friction in collection history for ASPs with new commercial payers.
- Market Education: Need for continued physician education on new smart apps and the utility of SHIELD for breast cancer and repeat testing.
- Operational: Automation technology for SHIELD requires FDA approval, expected late 2027, which could delay further COGS reductions.
- Market Adoption: While DTC is performing well, widespread adoption for non-oncology diseases and the transition from tissue-only to liquid-only paradigms requires ongoing validation and market shifting.
Management Commentary and Tone:
- Tone is highly confident and optimistic, describing all products as "hitting their stride" and precision medicine finally "coming to bear."
- Management views the market as vastly underestimated, particularly regarding therapy monitoring volumes and the potential for multi-disease screening.
- Emphasis on the "fruition" of precision oncology, leveraging hundreds of thousands of real-world data points to create new apps and clinical utilities.
- Management expressed surprise at the speed of reimbursement wins and the strength of DTC unit economics.
Analyst Questions and Answers:
- Q: Impact of new apps on revenue? A: Impacts are realized quickly; apps act like "iPhone launches" creating physician demand and new use cases.
- Q: Tissue vs. Liquid debate? A: Strategy is to own both modalities; tissue test is comprehensive (3 legs of the stool), while liquid offers speed and serial monitoring utility.
- Q: Therapy monitoring vs. MRD distinction? A: Short term they are linked to therapy selection; long term they converge as a unified market for patient monitoring.
- Q: Biopharma data materiality? A: Fastest growing segment; epigenomic data provides unique utility for drugs lacking traditional genomic biomarkers and enables early efficacy reads in trials.
- Q: FCF break-even swing factors? A: Primary drivers are ADLTA (expected to improve timeline) and SHIELD scale/COGS reduction; non-screening business is already profitable.
- Q: USPSCF vs. Commercial Reimbursement? A: USPSCF is a major catalyst for $0 cost-sharing and quality scores, but commercial coverage is already driving significant volume and growth.
Other Key Points:
- The company possesses a proprietary database of hundreds of thousands of patients with EMR, claims, and outcome data, enabling the rapid development of high-utility predictive apps.
- The "Reveal Ultra" product targets the specific need for speed and tissue-free testing while maintaining ultra-sensitive detection capabilities.
- State-level legislation (e.g., Pennsylvania) is successfully driving zero-cost access to SHIELD testing, providing a growth runway independent of federal USPSCF rules.
- Management confirmed no risk regarding the Q1 2027 ADLTA timeline, citing the simplicity of the application and precedent from the SHIELD approval cycle.
- Company
- GUARDANT HEALTH INC
- Keywords
- GUARDANT HEALTH INC